Resiquimod - an overview | ScienceDirect Topics
Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo- controlled, double-blind phase IIa studies - Journal of Hepatology
Recent clinical trends in Toll‐like receptor targeting therapeutics - Anwar - 2019 - Medicinal Research Reviews - Wiley Online Library
Article Reference
The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer | Nature Communications
Frontiers | Cancer Vaccines, Adjuvants, and Delivery Systems
Resiquimod (R848) | TLR7/8 Agonist | MedChemExpress
Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy. - Abstract - Europe PMC
Development of resiquimod-loaded modified PLA-based nanoparticles for cancer immunotherapy: A kinetic study - ScienceDirect
Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy | Oncotarget
Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01 - ScienceDirect
Pharmaceutics | Free Full-Text | TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases | HTML
Resiquimod (R848) | TLR7/8 Agonist | MedChemExpress
Systemic administration of low-dose resiquimod induces activation of... | Download Scientific Diagram
The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-γ–producing cells - Journal of Allergy and Clinical Immunology
Resiquimod for Prostate Cancer Treatment | IJN
Full article: Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
Topical Resiquimod Protects against Visceral Infection with Leishmania infantum chagasi in Mice | Clinical and Vaccine Immunology
Resiquimod PM induces T H 1 polarization of immune cells in the TME.... | Download Scientific Diagram
Resiquimod (R-848) | ≥99%(HPLC) | Selleck | TLR agonist
Resiquimod - an overview | ScienceDirect Topics
Frontiers | Anti-tumor Activity of Toll-Like Receptor 7 Agonists
Mesoporous Silica Nanoparticles as pH-Responsive Carrier for the Immune-Activating Drug Resiquimod Enhance the Local Immune Response in Mice | ACS Nano
Recent Advances in the Discovery and Delivery of TLR7/8 Agonists as Vaccine Adjuvants | ImmunoHorizons
TLR7 and TLR8 as targets in cancer therapy | Oncogene
Resiquimod | C17H22N4O2 - PubChem
The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer | Nature Communications
